RVPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Reviva Pharmaceuticals Holdings Inc (RVPH) is not a good buy for a beginner investor with a long-term strategy at this time. The stock is currently in a bearish technical trend, has weak financial performance, and faces significant challenges, including the need for equity dilution to fund a second Phase 3 study. Additionally, there are no strong positive catalysts or trading signals to justify a buy recommendation.
The stock is in a bearish trend with the MACD histogram below 0 and negatively expanding, RSI indicating oversold conditions at 9.316, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The pre-market price is $0.21, up 5.00%, but it remains below key resistance levels (R1: 0.266, R2: 0.283).
The RSI indicates the stock is oversold, which could attract short-term speculative interest. Analysts remain optimistic about brilaroxazine despite setbacks.
The FDA denied the company's request to file an NDA without a second Phase 3 study, requiring $60M-$75M in funding, likely leading to equity dilution. Financial performance is weak, with a YoY net income drop of -52.06% and EPS decline of -76.00%. No significant hedge fund, insider, or congressional trading activity is observed.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$4,010,773 (-52.06% YoY), and an EPS drop to -0.06 (-76.00% YoY). Gross margin remains at 0%.
Roth Capital lowered the price target from $3 to $1.50 while maintaining a Buy rating. Analysts are optimistic about brilaroxazine but anticipate equity dilution to fund the required Phase 3 study.
